Small Cell Lung Cancer (SCLC) Antikörper

Produktnummer ABIN6296686

Dieser Maus Monoklonal Antikörper detektiert spezifisch Small Cell Lung Cancer (SCLC) in IF und IHC (fro). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Small Cell Lung Cancer (SCLC) Antikörper (ABIN6296686)

Target: Small Cell Lung Cancer (SCLC)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails

Verwendungszweck: Mouse anti-Human SCLC Marker Antibody [Sodium Azide Free]

Spezifität: Cell surface

Aufreinigung: Lung Cancer-associated antigen isolated from small cell lung carcinoma-derived cell line was used as the immunogen for the SCLC Marker antibody.

Immunogen: Lung Cancer-associated antigen isolated from small cell lung carcinoma-derived cell line was used as the immunogen for the SCLC Marker antibody.

Anwendungsinformationen

Applikationshinweise: Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (Frozen): 0.5-1.0 μg/mL for 30 minutes at RT

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: In 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Antigendetails

Target: Small Cell Lung Cancer (SCLC)

Andere Bezeichnung: SCLC Marker

Hintergrund:

Target Description: This mAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80 % of all cases, and small cell, which accounts for roughly 20 % of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.